Nakano Yuichiro, Yoshimura Reiji, Nakano Hideki, Ikenouchi-Sugita Atsuko, Hori Hikaru, Umene-Nakano Wakako, Ueda Nobuhisa, Nakamura Jun
Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Hum Psychopharmacol. 2010 Mar;25(2):139-44. doi: 10.1002/hup.1102.
Nitric oxide (NO) is involved in pathophysiology of psychiatric disorders such as depression and schizophrenia. We hypothesize that plasma levels of NO and its metabolites (NO(x)) are decreased in patients with schizophrenia. To examine the hypothesis, we compared plasma NO(x) levels between 30 schizophrenic patients (M/F: 18/12, age: 38 +/- 15 years) and age- and sex-matched 30 healthy controls (M/F: 18/12, age: 41 +/- 19 years), and we also examined the effects of risperidone on plasma NO(x) levels in schizophrenic patients. The baseline plasma NO(x) levels were significantly lower in the schizophrenia group (1.85 +/- 0.70 microM) than those in control group (3.37 +/- 2.27 microM). A significantly negative correlation was found between plasma NO(x) levels and PANSS-N scores before risperidone administration (rho = -0.385, p = 0.0416). Treatment with risperidone significantly increased the plasma NO(x) levels by 8 weeks (before; 1.85 +/- 0.70 microM, after; 2.25 +/- 1.00 microM, p = 0.0491). These results suggest that NO might be one of the candidates factors which are associated with the pathophysiology of negative symptoms of schizophrenia.
一氧化氮（NO）参与抑郁症和精神分裂症等精神疾病的病理生理过程。我们假设精神分裂症患者血浆中NO及其代谢产物（NO(x)）水平降低。为验证该假设，我们比较了30例精神分裂症患者（男/女：18/12，年龄：38±15岁）与30例年龄和性别匹配的健康对照者（男/女：18/12，年龄：41±19岁）的血浆NO(x)水平，并且还研究了利培酮对精神分裂症患者血浆NO(x)水平的影响。精神分裂症组的基线血浆NO(x)水平（1.85±0.70微摩尔）显著低于对照组（3.37±2.27微摩尔）。在服用利培酮前，血浆NO(x)水平与PANSS-N评分之间存在显著负相关（rho = -0.385，p = 0.0416）。利培酮治疗8周后血浆NO(x)水平显著升高（治疗前；1.85±0.70微摩尔，治疗后；2.25±1.00微摩尔，p = 0.0491）。这些结果表明，NO可能是与精神分裂症阴性症状病理生理相关的候选因素之一。
